[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110051T1 - Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii - Google Patents

Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii

Info

Publication number
CY1110051T1
CY1110051T1 CY20101100469T CY101100469T CY1110051T1 CY 1110051 T1 CY1110051 T1 CY 1110051T1 CY 20101100469 T CY20101100469 T CY 20101100469T CY 101100469 T CY101100469 T CY 101100469T CY 1110051 T1 CY1110051 T1 CY 1110051T1
Authority
CY
Cyprus
Prior art keywords
tumors
tumour
present
relates
hla class
Prior art date
Application number
CY20101100469T
Other languages
English (en)
Inventor
Jörn Dengjel
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CY1110051T1 publication Critical patent/CY1110051T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ανοσοθεραπευτικές μεθόδους, και μόρια και κύτταρα για χρήση σε ανοσοθεραπευτικές μεθόδους. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με την ανοσοθεραπεία του καρκίνου. Η παρούσα εφεύρεση σχετίζεται επιπλέον με πεπτιδικούς επιτόπους Τ-βοηθητικών κυττάρων που σχετίζονται με όγκους, μόνους ή σε συνδυασμό με άλλα πεπτίδια που σχετίζονται με όγκους, που λειτουργούν ως φαρμακευτικά συστατικά συνθέσεων εμβολίων τα οποία διεγείρουν αντικαρκινικές ανοσολογικές απαντήσεις. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με 49 νέες πεπτιδικές αλληλουχίες που προέρχονται από HLA μόρια τάξης II ανθρώπινων καρκινικών κυτταρικών σειρών που μπορούν να χρησιμοποιηθούν σε συνθέσεις εμβολίων για να επιφέρουν αντικαρκινικές ανοσολογικές απαντήσεις.
CY20101100469T 2005-09-05 2010-05-27 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii CY1110051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05019254A EP1760088B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP07007915A EP1806359B1 (en) 2005-09-05 2005-09-05 Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number Publication Date
CY1110051T1 true CY1110051T1 (el) 2015-01-14

Family

ID=35170099

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20081100554T CY1107973T1 (el) 2005-09-05 2008-05-28 Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
CY20101100169T CY1109849T1 (el) 2005-09-05 2010-02-19 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
CY20101100469T CY1110051T1 (el) 2005-09-05 2010-05-27 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii
CY20101100520T CY1110187T1 (el) 2005-09-05 2010-06-11 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
CY20111101223T CY1112186T1 (el) 2005-09-05 2011-12-09 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081100554T CY1107973T1 (el) 2005-09-05 2008-05-28 Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
CY20101100169T CY1109849T1 (el) 2005-09-05 2010-02-19 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20101100520T CY1110187T1 (el) 2005-09-05 2010-06-11 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
CY20111101223T CY1112186T1 (el) 2005-09-05 2011-12-09 Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι

Country Status (23)

Country Link
US (6) US10196432B2 (el)
EP (6) EP1806359B1 (el)
JP (1) JP5627180B2 (el)
KR (3) KR101386827B1 (el)
CN (3) CN105440119A (el)
AT (5) ATE461214T1 (el)
AU (2) AU2006289290B2 (el)
BR (1) BRPI0615462A2 (el)
CA (2) CA2929252A1 (el)
CY (5) CY1107973T1 (el)
DE (4) DE602005020047D1 (el)
DK (5) DK1760088T3 (el)
EA (1) EA013876B1 (el)
ES (5) ES2341295T3 (el)
HK (2) HK1183678A1 (el)
HR (2) HRP20100128T1 (el)
NO (1) NO340870B1 (el)
NZ (2) NZ566104A (el)
PL (5) PL1806359T3 (el)
PT (5) PT1806358E (el)
SI (5) SI1760088T1 (el)
UA (1) UA98295C2 (el)
WO (1) WO2007028574A2 (el)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020047D1 (de) * 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
PT2660248E (pt) 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
EA018456B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
PL2567707T3 (pl) 2007-07-27 2017-03-31 Immatics Biotechnologies Gmbh Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
WO2009025116A1 (ja) * 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Cdh3ペプチド及びこれを含む薬剤
WO2009059011A2 (en) * 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
PL2105501T3 (pl) 2008-03-27 2016-03-31 Immatics Biotechnologies Gmbh Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
HUE024541T2 (hu) 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
PT2391654E (pt) * 2009-01-28 2015-11-19 Ind Tech Res Inst Biomarcadores na urina e séricos associados com nefropatia diabética
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
JP6032853B2 (ja) 2010-12-14 2016-11-30 イマティクス バイオテクノロジーズ ゲーエムベーハー 前立腺関連抗原分子由来ｈｌａ結合ペプチドおよびその使用方法
CN103502438A (zh) * 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
PL3456339T3 (pl) 2013-08-05 2022-03-21 Immatics Biotechnologies Gmbh Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
IL248203A0 (en) 2014-05-09 2016-11-30 Immatics Biotechnologies Gmbh Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MD3236985T3 (ro) 2014-12-23 2023-03-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor tipuri de cancere
KR20220167337A (ko) 2015-03-27 2022-12-20 이매틱스 바이오테크놀로지스 게엠베하 다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
SG10202107374UA (en) * 2015-06-19 2021-08-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
MY191654A (en) 2015-07-01 2022-07-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
ES2841507T3 (es) 2015-07-06 2021-07-08 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de esófago y otros tipos de cáncer
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI794761B (zh) 2015-08-28 2023-03-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP3436048A4 (en) * 2016-03-31 2019-11-27 Neon Therapeutics, Inc. NEOANTIGENES AND METHODS OF USE
CA3020162A1 (en) 2016-04-06 2017-10-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
JP2019520038A (ja) 2016-04-21 2019-07-18 イマティクス バイオテクノロジーズ ゲーエムベーハー 黒色腫およびその他のがんに対する免疫療法
CA3021159A1 (en) 2016-04-21 2017-10-26 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
WO2017212072A1 (en) * 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
SG10202108122YA (en) 2017-01-27 2021-09-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN110248672A (zh) * 2017-02-06 2019-09-17 中央研究院 重组蛋白及其用途
BR112019020959A2 (pt) 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
CR20190509A (es) 2017-04-10 2020-01-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
EP3648790A1 (en) 2017-07-07 2020-05-13 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
CA3075623C (en) 2017-09-18 2023-11-14 S & P Ingredient Development, Llc Low sodium salt substitute with potassium chloride
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
CN111684062A (zh) 2018-02-09 2020-09-18 伊玛提克斯美国公司 制造t细胞的方法
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202000693A (zh) * 2018-02-27 2020-01-01 美商葛利史東腫瘤科技公司 利用泛對偶基因（pan-allele）模型之新抗原鑑別
EP3539562A1 (en) * 2018-03-12 2019-09-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapeutic peptides
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
MX2021015033A (es) 2019-06-06 2022-01-18 Immatics Biotechnologies Gmbh Clasificacion con contraseleccion utilizando peptidos de secuencias similares.
CN110305209B (zh) * 2019-07-09 2022-09-13 福建医科大学附属第一医院 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
CN114555815A (zh) * 2019-07-30 2022-05-27 大学健康网络 T细胞受体及其使用方法
EP3827840A1 (en) * 2019-11-29 2021-06-02 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Teipp peptide variant and uses thereof
US11891427B2 (en) 2020-09-29 2024-02-06 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211999B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) * 1970-02-11 2012-09-04 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8212000B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (el) * 1977-09-20 1981-01-14 Licinvest Ag
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt) 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens
WO1993020202A1 (en) * 1992-04-03 1993-10-14 La Jolla Cancer Research Foundation Decorin fragments and methods of inhibiting cell regulatory factors
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
CA2175380A1 (en) * 1993-10-29 1995-05-04 Lan Bo Chen A novel tumor marker and novel method of isolating same
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0769963A4 (en) 1994-07-27 1999-07-28 Commw Scient Ind Res Org POLYEPITOPE VACCINES
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US6610821B1 (en) * 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
AU6241698A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
ATE302273T1 (de) 1997-10-15 2005-09-15 Pharis Biotec Gmbh Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) * 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
DE19938583A1 (de) 1999-08-18 2001-02-22 Buehler Ag Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US7118853B2 (en) * 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
WO2002050103A2 (en) 2000-12-20 2002-06-27 Glaxosmithkline Biologicals S.A. Tumour-related antigens
WO2002078516A2 (en) * 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1442295B1 (en) * 2001-08-13 2008-07-30 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
WO2003068940A2 (en) * 2002-02-14 2003-08-21 Curagen Corporation Complexes and methods of using same
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004110345A2 (en) * 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005014635A2 (en) * 2003-07-15 2005-02-17 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
DE602005020047D1 (de) * 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
DK1760089T3 (da) * 2005-09-05 2009-11-16 Immatics Biotechnologies Gmbh Tumor-associeret peptides bindende til human leukocyte antigen (HLA) class I eller II molecules og relateret anti-cancer vaccine
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells

Also Published As

Publication number Publication date
JP2010502173A (ja) 2010-01-28
DE602005005196T2 (de) 2008-06-26
ES2337399T3 (es) 2010-04-23
EP1806358A2 (en) 2007-07-11
US10618945B2 (en) 2020-04-14
NZ566104A (en) 2011-04-29
US20080207520A1 (en) 2008-08-28
DK1806359T3 (da) 2010-06-14
ES2373907T3 (es) 2012-02-10
HRP20100128T1 (hr) 2010-04-30
PT1806359E (pt) 2010-05-25
UA98295C2 (ru) 2012-05-10
DE602005005196D1 (de) 2008-04-17
DK1922335T3 (da) 2010-04-19
KR101386355B1 (ko) 2014-04-17
PT1806358E (pt) 2010-05-28
DE602005020047D1 (de) 2010-04-29
SI1806359T1 (sl) 2010-06-30
DK1806358T3 (da) 2010-06-28
HK1220709A1 (zh) 2017-05-12
EP1806358B1 (en) 2010-03-17
PL1922335T3 (pl) 2010-05-31
EP1760088A1 (en) 2007-03-07
WO2007028574A2 (en) 2007-03-15
EP1922335A2 (en) 2008-05-21
EP1806359A1 (en) 2007-07-11
HRP20110981T1 (hr) 2012-02-29
AU2010236029B2 (en) 2012-06-28
EA013876B1 (ru) 2010-08-30
KR20130019034A (ko) 2013-02-25
BRPI0615462A2 (pt) 2011-05-17
CN105440119A (zh) 2016-03-30
CA2929252A1 (en) 2007-03-15
EP2135878B1 (en) 2011-11-09
SI1922335T1 (sl) 2010-04-30
ES2341802T3 (es) 2010-06-28
CA2621389A1 (en) 2007-03-15
DK1760088T3 (da) 2008-06-09
CN103059104A (zh) 2013-04-24
PT1760088E (pt) 2008-05-14
SI2135878T1 (sl) 2012-03-30
PL1760088T3 (pl) 2008-10-31
PL1806359T3 (pl) 2010-08-31
NO340870B1 (no) 2017-07-03
JP5627180B2 (ja) 2014-11-19
US20100040590A1 (en) 2010-02-18
US7833969B2 (en) 2010-11-16
US20080206218A1 (en) 2008-08-28
AU2006289290B2 (en) 2010-11-25
ATE532795T1 (de) 2011-11-15
ES2302546T3 (es) 2008-07-16
US20080206217A1 (en) 2008-08-28
WO2007028574A9 (en) 2008-05-02
WO2007028574A3 (en) 2007-05-24
SI1806358T1 (sl) 2010-06-30
DE602006011030D1 (de) 2010-01-21
NZ588813A (en) 2011-06-30
CY1107973T1 (el) 2013-09-04
PL1806358T3 (pl) 2010-08-31
ES2341295T3 (es) 2010-06-17
NO20081683L (no) 2008-04-04
KR20080052643A (ko) 2008-06-11
AU2010236029A1 (en) 2010-11-18
CN101287754A (zh) 2008-10-15
EP2135878A1 (en) 2009-12-23
US7807642B2 (en) 2010-10-05
EP1806358A3 (en) 2007-10-03
US20160115212A1 (en) 2016-04-28
KR101386827B1 (ko) 2014-04-17
ATE451388T1 (de) 2009-12-15
CN103059104B (zh) 2015-10-28
ATE461215T1 (de) 2010-04-15
CA2621389C (en) 2016-07-19
AU2006289290A1 (en) 2007-03-15
CY1112186T1 (el) 2015-12-09
KR20130019033A (ko) 2013-02-25
SI1760088T1 (sl) 2008-06-30
PL2135878T3 (pl) 2012-06-29
ATE461214T1 (de) 2010-04-15
PT1922335E (pt) 2010-03-03
PT2135878E (pt) 2012-01-05
US10196432B2 (en) 2019-02-05
KR101386790B1 (ko) 2014-04-21
CN101287754B (zh) 2013-02-13
HK1183678A1 (en) 2014-01-03
EP1922335B1 (en) 2009-12-09
ATE388164T1 (de) 2008-03-15
US20080206216A1 (en) 2008-08-28
DE602005020046D1 (de) 2010-04-29
EP1806359B1 (en) 2010-03-17
EA200800677A1 (ru) 2008-08-29
EP2138509A1 (en) 2009-12-30
CY1109849T1 (el) 2014-09-10
CY1110187T1 (el) 2015-01-14
DK2135878T3 (da) 2012-02-27
EP1760088B1 (en) 2008-03-05
US7833970B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
CY1110051T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii
CY1110536T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii και σχετικο αντικαρκινικο εμβολιο
SI1794190T1 (sl) Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope